An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer
Malignant pleural effusions are common in late stage non-small cell lung cancer and can lead
to significantly increased morbidity in this patient population. The majority of patients
are symptomatic due to their malignant effusions. The recurrence rates are thought to be
quite high overall and may approach 100% without any further treatment.Currently there is no
available non-invasive, medical means for controlling the effusions other than systemic
chemotherapy.Zoledronic acid has been shown in a mouse model of malignant pleural effusion
to decrease fluid accumulation and tumor dissemination while prolonging survival.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of Control (Lack of Need for Palliative Intervention of Malignant Pleural Effusions) in Patients With Non Small Cell Lung Cancer Treated With Standard Regimens of Cytotoxic Chemotherapy With the Addition of Zometa
Todd Sheppard, M.D.
Rochester General Hospital
United States: Institutional Review Board
|Rochester General Hospital||Rochester, New York 14621|